Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on June 2, 2026, covering events occurring between May 19, 2026, and June 2, 2026. The filing details material definitive agreements involving the exchange of preferred stock for common stock and the adjournment of the company's 2026 Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt levels, or liquidity ratios. The document focuses exclusively on capital structure transactions and corporate governance events.
Material Changes and Transactions
- Preferred Stock Issuance: On May 19, 2026, the Company issued 408 shares of Series Q Perpetual Preferred Stock to Streeterville Capital, LLC.
- First Exchange Transaction: On May 26, 2026, the Company issued 31,958 shares of Common Stock to Streeterville in exchange for 3.72 shares of Series Q Preferred Stock. The exchanged preferred shares were cancelled and retired.
- Second Exchange Transaction: On June 1, 2026, the Company issued 32,710 shares of Common Stock to Streeterville in exchange for 4.2 shares of Series Q Preferred Stock. These preferred shares were also cancelled and retired.
- Regulatory Basis: The common stock issuances were made in reliance on the Section 3(a)(9) exemption from registration under the Securities Act of 1933.
Corporate Governance and Outlook
The Company reconvened its 2026 Annual Meeting of Stockholders on June 2, 2026, which had previously been adjourned on May 22, 2026. Following the filing of a Supplement to the Proxy Statement on May 29, 2026, the Company decided to further adjourn the meeting to Monday, June 8, 2026, at 8:30 a.m. Pacific Time. This extension allows stockholders additional time to review new information regarding certain proposals. The record date for the meeting remains April 15, 2026.
Investor Verification Checklist
- Review the full text of the Streeterville Exchange Agreements (Exhibits 10.1 and 10.2) to understand the specific terms, conversion rates, and covenants.
- Examine the Supplement to the Proxy Statement filed on May 29, 2026, to understand the additional information prompting the meeting adjournment.
- Verify the total dilution impact of the 64,668 shares of Common Stock issued to Streeterville in these two transactions.
- Confirm the remaining outstanding balance of Series Q Perpetual Preferred Stock following the retirement of 7.92 shares.